OverviewSuggest Edit

Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. Its focus areas include urology, immunology, cardiology, infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. The company develops XTANDI, an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation-positive; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); Evrenzo, an oral treatment for anemia associated with chronic kidney disease (CKD), and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used to suppress organ rejection following a transplant.
TypePublic
Founded1923
HQTokyo, JP
Websiteastellas.com
Employee Ratings3.8
Overall CultureF

Latest Updates

Employees (est.) (Mar 2021)15,455(-2%)
Job Openings236
Revenue (FY, 2020)$1.2 T(-3%)
Share Price (May 2022)¥2 K
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Astellas Pharma

Kenji Yasukawa

Kenji Yasukawa

Representative Director, President and CEO
Naoki Okamura

Naoki Okamura

Representative Director, Executive Vice President, Chief Strategy Officer
Fumiaki Sakurai

Fumiaki Sakurai

Chief Administrative Officer and Chief Ethics & Compliance Officer
Yukio Matsui

Yukio Matsui

Chief Commercial Officer
Minoru Kikuoka

Minoru Kikuoka

Chief Financial Officer
Hideki Shima

Hideki Shima

Chief Manufacturing Officer
Show more

Astellas Pharma Office Locations

Astellas Pharma has offices in Tokyo, Takahagi, Takaoka, Toyama and in 56 other locations
Tokyo, JP (HQ)
2-5-1, Nihonbashi-Honcho, Chuo-ku
Takahagi, JP
160-2 Akahama
Takaoka, JP
30 Toidesakaemachi
Toyama, JP
2-178 Kōjinmachi
Tsukuba, JP
21, Miyukigaoka
Tsukuba, JP
5-2-3, Tokodai
Show all (63)

Astellas Pharma Financials and Metrics

Astellas Pharma Revenue

Astellas Pharma's revenue was reported to be $1.25 t in FY, 2020
USD

Revenue (Q3, 2021)

340.6b

Gross profit (Q3, 2021)

318.3b

Net income (Q3, 2021)

60.9b

EBITDA (Q3, 2021)

108.6b

EBIT (Q3, 2021)

79.2b

Market capitalization (16-May-2022)

3.6t

Closing stock price (16-May-2022)

2.0k

Cash (31-Dec-2021)

350.2b

EV

3.3t
Astellas Pharma's current market capitalization is ¥3.6 t.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.3t1.3t1.3t1.2t

Cost of goods sold

(229.4b)(228.6b)(210.3b)(173.4b)

Gross profit

1.1t1.1t1.1t1.1t

R&D expense

(220.8b)(208.7b)(224.2b)(224.5b)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

329.1b318.0b357.9b334.1b316.3b338.1b307.0b308.5b325.4b326.1b325.5b340.6b

Cost of goods sold

(54.7b)(57.0b)(68.3b)(53.5b)(54.2b)(65.6b)(41.7b)(42.0b)(50.0b)(44.1b)(43.6b)(47.8b)

Gross profit

274.4b261.0b289.7b285.2b264.8b280.3b267.6b268.6b278.2b282.5b284.4b318.3b

R&D expense

(52.1b)(47.4b)(50.4b)(53.5b)(51.5b)(54.8b)(57.3b)(54.4b)(57.1b)(58.3b)(60.7b)(58.6b)
Annual
JPYFY, 2017FY, 2018FY, 2019FY, 2020

Cash

328.7b297.5b313.1b326.1b

Accounts Receivable

319.5b342.6b347.0b343.2b

Prepaid Expenses

9.1b12.7b11.5b

Inventories

147.6b151.5b151.0b164.1b
Quarterly
JPYQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

309.7b306.9b331.3b259.4b311.4b277.6b239.9b286.7b306.5b301.9b318.3b350.2b

Accounts Receivable

333.5b323.1b347.1b358.8b335.8b366.9b360.7b332.7b345.6b364.2b357.8b373.9b

Inventories

145.6b149.1b145.2b150.5b148.0b149.3b155.1b155.7b155.7b157.3b148.7b151.6b
Annual
JPYFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

218.1b249.0b245.4b145.3b

Depreciation and Amortization

64.9b63.5b66.4b72.7b

Inventories

37.8b(5.5b)(6.0b)(2.3b)

Accounts Payable

(43.8b)40.8b(21.4b)(51.6b)
Quarterly
JPYQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

64.5b128.3b212.8b76.5b161.6b239.2b60.2b89.1b164.2b35.8b89.1b167.4b

Depreciation and Amortization

16.1b31.8b47.8b17.0b31.1b48.3b18.0b35.9b54.1b18.1b37.1b58.6b

Inventories

2.4b3.6b2.0b(3.5b)(4.6b)(988.0m)(3.2b)(2.9b)(1.5b)8.3b15.4b17.3b

Accounts Payable

(5.9b)(11.4b)44.6b(45.0b)(24.5b)(42.7b)(30.2b)(50.8b)(59.2b)(13.2b)(8.8b)1.1b
USDFY, 2018

Revenue/Employee

78.3m
Show all financial metrics

Astellas Pharma Operating Metrics

FY, 2020Oct, 2020

Phase I Trials Products (Immunology)

11

Phase I Trials Products (Oncology)

1

Phase II Trials Products (Oncology)

1

Phase III Trials Products (Oncology)

44
Show all operating metrics

Astellas Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Iota BiosciencesOctober 15, 2020$127.5 m
Nanna TherapeuticsApril 21, 2020£12 m
XyphosDecember 26, 2019
Audentes TherapeuticsDecember 02, 2019$3 b
Potenza TherapeuticsDecember 14, 2018$405 m
QuetheraAugust 14, 2018£85 m
Universal Cells Inc.February 13, 2018
MitobridgeDecember 01, 2017
OgedaApril 02, 2017€500 m
Ganymed PharmaceuticalsOctober 28, 2016$1.4 b
Show more

Astellas Pharma Revenue Breakdown

Embed Graph

Astellas Pharma revenue breakdown by business segment: 36.7% from XTANDI, 13.1% from BETANIS/MYRBETRIQ/BETMIGA, 35.6% from OTHER NONDISCLOSED and 14.6% from PROGRAF

Astellas Pharma revenue breakdown by geographic segment: 22.3% from Japan, 23.5% from Established Markets, 8.9% from International, 37.9% from United States and 7.4% from Other

Show all human capital metrics

Astellas Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Astellas Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Astellas Pharma Online and Social Media Presence

Embed Graph

Astellas Pharma Company Culture

  • Overall Culture

    F

    34/100

  • CEO Rating

    F

    30/100

  • Compensation

    F

    10/100

Learn more on Comparably

Astellas Pharma News and Updates

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will share new research during the 2022 American...

Astellas DX Strategy Series Vol.1: Utilizing DX to Create and Maximize VALUE for Patients

DX has huge potential to transform the pharma industry, and Astellas is harnessing digital technology on a global scale to deliver more VALUE for patients.

Worldwide Stem Cells Industry to 2028 - Featuring Astellas Pharma, BioTime and Takara Bio Among Others

Dublin, April 13, 2022 (GLOBE NEWSWIRE) -- The "Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering. This report on the global stem cells market studies past as well as current growth trends …

Reinvigorating the immune system to find new ways to cure cancer

Primary Focus Lead Peter Sandor believes we will someday cure cancer. He discusses Astellas' strategy to leverage its broad expertise, experience, and proprietary technologies in oncology to bring innovative treatments to more patients.

Astellas’ VALUE powered by people — New Challenge of HR

Katsuyoshi Sugita has been involved in HR management at global companies for many years and was appointed Head of Astellas’ HR division in May 2021. When I joined Astellas in May 2021 as the Head of the HR division, the company was much more globalized than I had assumed. Objectively speaking, not m…
Show more

Astellas Pharma Frequently Asked Questions

  • When was Astellas Pharma founded?

    Astellas Pharma was founded in 1923.

  • Who are Astellas Pharma key executives?

    Astellas Pharma's key executives are Kenji Yasukawa, Naoki Okamura and Fumiaki Sakurai.

  • How many employees does Astellas Pharma have?

    Astellas Pharma has 15,455 employees.

  • What is Astellas Pharma revenue?

    Latest Astellas Pharma annual revenue is $1.2 t.

  • What is Astellas Pharma revenue per employee?

    Latest Astellas Pharma revenue per employee is $80.8 m.

  • Who are Astellas Pharma competitors?

    Competitors of Astellas Pharma include Shionogi, Nipro Corporation and Hetero.

  • Where is Astellas Pharma headquarters?

    Astellas Pharma headquarters is located at 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo.

  • Where are Astellas Pharma offices?

    Astellas Pharma has offices in Tokyo, Takahagi, Takaoka, Toyama and in 56 other locations.

  • How many offices does Astellas Pharma have?

    Astellas Pharma has 63 offices.